


# **DIURETICS**

## **Part 1**

**Dr. Hanan Hagar**  
**Pharmacology Department**



# KIDNEY

- Nephron is the unit of the kidney
- It is classified structurally and functionally into different zones
  - Glomerulus
  - Proximal convoluted tubule
  - Descending loop of Henle
  - Ascending loop of Henle
  - Distal convoluted tubule
  - Collecting duct



# REGULATION OF FLUIDS AND ELECTROLYTES





Figure 15-1. Tubule transport systems and sites of action of diuretics.



# SITES FOR SOLUTES AND WATER TRANSPORT ALONG THE NEPHRON



# **FUNCTION OF THE KIDNEY**

- **Kidney is responsible for regulation of fluids and electrolytes**
- **It controls:**
  - **volume of the urine**
  - **ionic composition of the urine**



- **Kidney do its function through three processes**
  - **Glomerular filtration**
  - **Passive tubular reabsorption**
  - **Active tubular secretion**



## ○ **Glomerular filtration:**

- **16-20 % of blood entering the kidney is filtered**
- **Filtrate contains glucose, amino acids, sodium bicarbonates, organic solutes and electrolytes as sodium, potassium, chloride**



## ○ Proximal convoluted tubule:

- Located in the cortex
- Responsible for reabsorption of
  - all glucose, amino acids,
  - organic solutes
  - electrolytes as
    - sodium chloride (NaCl) (66% of Na)
    - Potassium ( $K^+$  , 66 %)
    - sodium bicarbonate ( $NaHCO_3$ , 85%)






## ○ Proximal convoluted tubule:


- $\text{NaHCO}_3$  is reabsorbed by action of enzyme carbonic anhydrase (*luminal membrane of proximal tubular cells*).
- water is absorbed passively following salts to maintain osmolarity in tubular fluids (60%).
- PCT is the site of organic acids or bases secretory systems




# CARBONIC ANHYDRASE



# organic acids or bases secretory systems

- **Organic base secretory system**  
responsible for secretion of bases into  
luminal fluid e.g. choline and creatinine
  - **Organic acid secretory system**  
responsible for secretion of acids into  
luminal tubular fluid e.g. uric acid,  
NSAIDs, antibiotics and diuretics.
  - are saturable
- 




## ○ Descending loop of Henle

- Located in the medulla
- *In thin descending loop of Henle :*  
water is reabsorped by osmotic forces  
in hypertonic medullary interstitium  
(*counter current mechanism*)
- The filtrate (isotonic) becomes  
concentrated along this descending  
loop due to water reabsorption
- Diuretics (*impermeant mannitol*)





# Countercurrent Mechanism



## ○ Ascending loop of Henle

- Is impermeable to water
- *In Thick ascending loop of Henle (TAL)* is responsible for active reabsorption of Na, K and Cl (25% of Na) via transport system in luminal membrane called  **$\text{Na}^+ / \text{K}^+ / 2\text{Cl}^-$  co-transporter**
- TAL is called **the diluting segment**




## ○ Ascending loop of Henle


- Ca and Mg enter the interstitial fluid via paracellular pathway
- Loop diuretics act on this segment to inhibit NaCl, Ca, Mg reabsorption



# ASCENDING LOOP OF HENLE



# Tubular Reabsorption and Secretion






## ○ Distal convoluted tubule (DCT)

- Is impermeable to water
- Responsible for active reabsorption of NaCl (10%) via transport system **Na/Cl transporter in luminal membrane of**
- $\text{Ca}^{2+}$  actively reabsorbed via Ca channel and  $\text{Na}^+/\text{Ca}^{2+}$  exchanger in basolateral membrane



# DISTAL CONVOLUTED TUBULES (DCT)




## ○ Collecting tubule


- Principal cells are responsible for reabsorption of Na (**in exchange for K via Na/K-ATPase**) and water
- Intercalated cells affect H secretion
- Aldosterone receptors located in the principle cells influence Na reabsorption and K secretion
- Antidiuretic hormone (ADH) promotes reabsorption of water.



# COLLECTED TUBULES (CT)



# COLLECTED TUBULES (CT)





## FUNCTION OF DIFFERENT PARTS OF NEPHRON

segment	Function	transporter	Diuretic drug
PCT	Reabsorption of 66% Na, K, Ca, Mg, 100% glucose and amino acids; 85% NaHCO <sub>3</sub>	Na/H transporter, Carbonic anhydrase enzyme	Carbonic anhydrase inhibitors
PST	Secretion and reabsorption of organic acids and bases	Acid & base transporter	None
TAL	Active reabsorption 25% Na, K, Cl Secondary reabsorption Ca, Mg	Na/K/2Cl transporter	Loop diuretics
DCT	Active tubular reabsorption of 5% Na, Cl, Ca	Na and Cl cotransporter	Thiazide diuretics
CCT	Na reabsorption K & H secretion	Na channels K & H transporter	K-sparing diuretics

- Diuretics : drugs that increase urine volume.
- Natriuretics: drugs that increase urinary excretion of sodium.
- Increased urinary sodium excretion result in increased water excretion.



# **DIURETICS**

**are classified into**

- Carbonic Anhydrase Inhibitors**
- Loop Diuretics**
- Thiazides**
- Potassium-Sparing Diuretics**
- Osmotic Diuretics**




# SITES OF ACTION OF DIURETICS

## ACETAZOLAMIDE

- A carbonic anhydrase inhibitor that inhibits the reabsorption of  $\text{HCO}_3^-$  in the proximal convoluted tubule.
- Weak diuretic properties.

## THIAZIDES

- Inhibit reabsorption of  $\text{Na}^+$  and  $\text{Cl}^-$  in the distal convoluted tubule, resulting in retention of water.
- Most commonly used diuretics.



# **CARBONIC ANHYDRASE INHIBITORS**

## **ACETAZOLAMIDE**

**Chemistry:** Sulphonamide derivative

**Mechanism of action:**

Inhibits carbonic anhydrase enzyme in PCT thus interferes with  $\text{NaHCO}_3$  reabsorption.






# Pharmacodynamics:

- Increase excretion of bicarbonate, sodium, potassium “alkaline diuresis”
- Metabolic acidosis.
- Phosphate excretion is increased
- Weak diuretics.
- Decreases after several days  
(*self-limiting as the blood bicarbonate falls*).



## PHARMACODYNAMICS OF CA INHIBITORS:






- **Pharmacokinetics:**
- given orally or parenterally.
- Onset of action is rapid (30 min).
- Duration of action 12 h.
- Excreted by active secretion in proximal convoluted tubules
- *(dose should be reduced in renal insufficiency)*



## Therapeutic uses:

- Open angle glaucoma (*reduce formation of aqueous humor by blocking carbonic anhydrase in ciliary body of eye*).
- Epilepsy (*decrease cerebrospinal fluid -CSF*).
- Urinary alkalization to enhance excretion of uric acid and cystine which are soluble in alkaline urine

## Therapeutic uses:

- In prophylaxis of acute mountain sickness (*to decrease CSF and pH of brain*). Given five days before the ascent .
  - Acute mountain sickness is characterized by nausea, headache, weakness, pulmonary and cerebral edema
  - Hyperphosphatemia
  - Metabolic alkalosis
- 

## Adverse effects:

- **Metabolic acidosis.**
- **Renal stones (calcium phosphate)**
- **Hypokalemia (potassium loss).**
- **Drowsiness, Paresthesia.**



## Contraindication

- liver cirrhosis: it decrease  $\text{NH}_4$  excretion & hepatic encephalopathy
- Renal failure: it accumulates to produce nervous system toxicity



# **NEW CARBONIC ANHYDRASE INHIBITORS**

## **○ Dorzolamide**

- Topically active.**
- Reduce intraocular pressure equal to oral agents.**
- Have no diuretic or systemic metabolic effects.**



# THIAZIDES DIURETICS

## ○ Chemistry:

- are sulphonamide derivatives.
- Chlorothiazide, hydrochlorothiazide
- Chlorthalidone, indapamide are *thiazide-like diuretics*.





## ○ Pharmacokinetics:

- given orally.
- Chlorothiazide- injection available.
- Chlorothiazide is the least potent
- All have slow onset
- All have long duration of action (40 h)
- All are secreted by active tubular secretion (organic acid secretory system) *may interfere with uric acid secretion and cause hyperuricemia*




## **MECHANISM OF ACTION**

- **Affect distal convoluted tubules (DCT)**
- **Decreases NaCl reabsorption via inhibition of Na/Cl cotransporter on the luminal membrane of DCT**



# MECHANISM OF ACTION OF THIAZIDE DIURETICS




## **PHARMACODYNAMICS:**

- **Increased NaCl excretion in urine**
- **loss of K in urine (Hypokalemia)**
- **loss of magnesium in urine**
- **Increase calcium reabsorption**
- **Mild vasodilator action.**
- **Hyperglycemia: impaired release of insulin, decreased tissue utilization of glucose.**



# EFFECTS OF THIAZIDE DIURETICS



## THERAPEUTIC USES:

- most widely used
  - Essential hypertension (*cheap-well tolerated*)
  - Heart Failure (*to reduce extracellular volume*)
  - Severe edema of cirrhosis.
  - Nephrolithiasis or hypercalciuria (*to prevent kidney stone formation of calcium*)
  - Nephrogenic diabetes insipidus (*decrease blood volume and GFR*)



## **ADVERSE EFFECTS:**

- **Fluid and electrolyte imbalance**
- **Hypokalemic (Potassium depletion)**
- **Hyponatremia**
- **Hypovolemia (volume depletion)**
- **Metabolic alkalosis.**
- **Hyperuricaemia (gout)**
- **Hypercalcemia**
- **Hyperglycaemia:**
- **Hyperlipidemia: increased plasma cholesterol.**
- **Hypersensitivity**





## **Contraindications:**

- **Liver cirrhosis → encephalopathy.**
- **Borderline renal failure.**




# LOOP DIURETICS

## HIGH CEILING DIURETICS

- Furosemide
- Torsemide
- Bumetanide
- Ethcrynac acid
  
- Chemistry:
  - Sulphonamide derivatives.




# PHARMACOKINETICS OF LOOP DIURETICS

- Given orally or I. V.
  - Has fast onset of action (suitable for emergency)
  - Onset of action is more rapid after I.V. route.
  - Have short duration of action (2-4 h)
  - Excreted by active tubular secretion of weak acids into urine (*compete with uric acid for renal secretory system*) .
- 

## MECHANISM OF ACTION OF LOOP DIURETICS

- Act on Thick ascending loop of Henle (TAL).
- Inhibit  $\text{Na}^+ / \text{K}^+ / 2 \text{Cl}^-$  transport system reducing NaCl reabsorption (25-30%).
- The most efficacious diuretics
- Inhibit  $\text{Ca}^{++}$  and  $\text{Mg}^{++}$  reabsorption.

# ASCENDING LOOP OF HENLE




## **Pharmacodynamics of loop diuretics:**

- **↑ urinary excretion of  $\text{Na}^+$  ,  $\text{K}^+$   $\text{Ca}^{++}$  and  $\text{Mg}^{++}$**
- **↑ urine volume**
- **Haemodynamic effects:**
  - **Increase renal blood flow.**
  - **Decrease renal vascular resistance**
  - **Increase prostaglandin synthesis**



# Effects of loop diuretics:





# **THERAPEUTIC USES OF LOOP DIURETICS**

- **Are widely used drugs (drug of choice) for emergency :**
- **Acute pulmonary edema of heart failure .**
- **Acute hyperkalaemia.**
- **Acute hypercalcaemia**
- **Congestive heart failure**



## Adverse effects of loop diuretics:

- Metabolic alkalosis.
- Acute Hypovolemia
- Hyponatraemia.
- Hypokalemia  
(dietary K supplementation or K-sparing diuretics).



## Adverse effects of loop diuretics:

- Hypomagnesaemia (oral supplementation)
- Hyperuricemia (*increase gouty attack*).
- Ototoxicity
- Allergic reactions.



# POTASSIUM-SPARING DIURETICS

## Drugs:

- **Spironolactone.**
- Triamterene.
- Amiloride.



# PHARMACOKINETICS:

- **Spironolactone**
- **Rapidly absorbed orally**
- **Has slow onset of action, takes several days**
- **Converted into active metabolite**
- **Induces CYT P450**




## Mechanism of action of k-sparing diuretics

- Spironolactone is a synthetic steroid that acts as a competitive antagonist to aldosterone at its cytoplasmic receptors
- Act in collecting tubules and ducts by inhibiting Na reabsorption and K & H secretion (*K-sparing effect*).



# COLLECTED TUBULES (CT)



# Pharmacodynamics of K-sparing diuretics

Increase urinary Na excretion


Decrease urinary K excretion  
(**Hyperkalemia**)

Decrease H secretion (**acidosis**)





## **THERAPEUTIC USES:**

- **Drug of choice for patients with hepatic cirrhosis**
  - **In mineralocorticoid hypersecretion e.g. Conn's syndrome**
  - **Secondary hyperaldosteronism: CHF, hepatic cirrhosis, nephrotic syndrome.**
  - **Diuretics in combination with thiazide or loop diuretics (to correct for hypokalemia).**
- 

# Adverse Effects

- **Gynaecomastia**
- **Hyperkalaemia.**
- **Metabolic acidosis.**
- **GIT upset and peptic ulcer**



# Contraindications:

- **Hyperkalaemia:** as in chronic renal failure, K<sup>+</sup> supplementation,  $\beta$ -blockers or ACE inhibitors.
- **Patients with liver disease,** dose adjustment is needed.



# OSMOTIC DIURETICS

## **Mannitol**

- **Poorly absorbed**
- **Given intravenously.**
- **Distributed in extracellular compartments**
- **Not metabolized**



# Mannitol

- Undergoes glomerular filtration **BUT not reabsorbed or secreted.**
- Acts in proximal tubules & descending loop of Henle by **osmotic effect.**
- Retains water within the tubules (diuresis).
- Has a secondary effect on reducing sodium reabsorption.



# Therapeutic Uses:

- Cerebral edema (increased intracranial pressure).
- Acute renal failure due to shock, trauma, drug toxicities (maintain urine flow- preserve kidney function).
- Glaucoma.



# Adverse Effects:

- Extracellular water expansion  
*(extracts water from cells)*
- Dehydration
- Hypernatremia
- Headache, Nausea, Vomiting
- Adequate water replacement is required.




Diuretics	Mechanism of action	Effects
<b>CA inhibitors</b> <b>Acetohexamide</b> <b>Dorzolamide</b>	Inhibition of $\text{NaHCO}_3$ reabsorption in <b>PCT</b>	$\uparrow$ Urinary Na $\text{HCO}_3$ , K Urinary alkalosis Metabolic acidosis
<b>Osmotic diuretic</b> <b>Mannitol</b>	Osmotic effect in <b>PCT &amp; DLH</b>	$\uparrow$ Urine excretion $\uparrow$ Little Na
<b>Loop diuretics</b> <b>Furosemide</b>	Na/K/2Cl transporter in <b>TAL</b> <b>the most effective</b>	$\uparrow$ Urinary Na, K, Ca, Mg
<b>Thiazide diuretics</b> <b>Chlorothiazide</b> <b>hydrochlorothiazide</b>	Na and Cl cotransporter in <b>DCT</b>	$\uparrow$ Urinary Na, K, Mg <b>BUT</b> $\downarrow$ urinary Ca <b>(hypercalcemia)</b> Metabolic alkalosis
<b>K-sparing diuretic</b> <b>Spironolactone.</b>	competitive antagonist of aldosterone in <b>CCT</b>	$\uparrow$ Urinary Na $\downarrow$ K, H secretion Metabolic acidosis



Diuretics	Uses
<b>CA inhibitors</b> <b>Acetohexamide</b> <b>Dorzolamide (topically)</b> <b>for glaucoma</b>	<b>Glaucoma, epilepsy</b> <b>Mountain sickness</b>
<b>Osmotic diuretic</b> <b>Mannitol</b>	<ul style="list-style-type: none"> <li>•Cerebral edema</li> <li>•Acute renal failure</li> </ul>
<b>Loop diuretics</b> <b>Furosemide</b>	<b>Pulmonary fibrosis (Drug of choice)</b> <b>Heart failure</b> <b>Hyperkalemia, Hypercalcemia</b>
<b>Thiazide diuretics</b> <b>Chlorothiazide</b> <b>hydrochlorothiazide</b>	<b>Commonly used</b> <b>Hypertension, heart failure,</b> <b>hypercalciuria, kidney stones, diabetes</b> <b>insipidus</b>
<b>K-sparing diuretic</b> <b>Spironolactone.</b>	<b>Hepatic cirrhosis</b> <b>(Drug of choice)</b>

Diuretics	Side effects
<b>CA inhibitors</b> <b>Acetohexamide</b> <b>Dorzolamide</b>	<b>Metabolic acidosis , Urinary alkalosis</b> <b>Hypokalemia</b>
<b>Osmotic diuretic</b> <b>Mannitol</b>	<b>Extracellular water expansion</b> <b>Dehydration</b> <b>Hypernatremia</b>
<b>Loop diuretics</b> <b>Furosemide</b>	<b>Hypokalemia,</b> <b>hypovolemia, hyponatremia,</b> <b>hypomagnesemia, hypocalcemia</b> <b>Precipitate gout, alkalosis</b>
<b>Thiazide diuretics</b> <b>Chlorothiazide</b> <b>hydrochlorothiazide</b>	<b>Hypokalemia, hyponatremia, hypovolemia,</b> <b>hypomagnesemia, hypercalcemia</b> <b>Alkalosis, precipitate gout</b> <b>Hyperlipidemia, hyperglycemia</b>
<b>K-sparing diuretic</b> <b>Spironolactone.</b>	<b>Gynaecomastia</b> <b>Hyperkalaemia, Metabolic acidosis.</b> <b>GIT upset and peptic ulcer</b>

# PROSTATIC HYPERTROPHY



# PROSTATIC HYPERTROPHY

- is a benign enlargement of the prostate an increase in size of the prostate in middle-aged and elderly men.
- occurs by some drugs as alpha agonists (*contraction of smooth muscles*) and antimuscrinics (*urinary retention*).



## BPH is characterized by:

- Hyperplasia of prostatic cells
- Partial or complete obstruction of the urethra, which interferes with the normal flow of urine.
- dysuria (painful urination), increased risk of urinary tract infections, and urinary retention.



# Treatments of BPH

- Alpha blockers ( $\alpha_1$ -adrenergic receptor antagonists) are the most common choice as tamsulosin, and alfuzosin
- act by relaxing smooth muscle in the prostate and the bladder neck, thus decreasing the blockage of urine flow.



## ○ 5 $\alpha$ -reductase inhibitors

- finasteride
- Inhibits 5 $\alpha$ -reductase, which in turn inhibits production of DHT, a hormone responsible for enlarging the prostate.
- Effects may take longer to appear than alpha blockers, but they persist for many years.

**Side effects:**

erectile dysfunction

